Drug Trial Radar · NCT05934513
A Study of GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Last checked: Nov 19, 2026Latest source record: Dec 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
95
Planned (sponsor's estimate)
Start
Sep 6, 2023
Primary completion
Dec 30, 2025
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Genfleet Therapeutics (Shanghai) Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicentre, open-label phase Ib/II study. The purpose of the study is to assess the efficacy, safety/ tolerability and pharmacokinetic of GFH009 monotherapy in patients with relapsed or refractory peripheral T-cell lymphoma
Conditions
- Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Interventions
GFH009Drug
patients are planned to be administrated with GFH009 every week in a 21 days cycle, intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ib: adverse eventsTime frame: From Screening (Day -28 to Day-1) until disease progression or survival until death (approximately 6 months)
- Phase II: Objective Response RateTime frame: From Screening (Day -28 to Day-1) until disease progression or survival until death (approximately 6 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guanzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.